1 Min Read
Nov 17 (Reuters) - Celldex Therapeutics Inc
* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.